1,4-butanediyl diacrylate

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

other information

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1963

Report date:

1963

Materials and methods

Test guideline

Qualifier:

no guideline followed

Principles of method if other than guideline:

The substance preparations were injected into the peritoneal cavity of mice. The mice were observed for 7 days an the LD50 was calculated.

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

1,4-butanediyl diacrylate

EC Number:

213-979-6

EC Name:

1,4-butanediyl diacrylate

Cas Number:

1070-70-8

Molecular formula:

C10H14O4

IUPAC Name:

4-(prop-2-enoyloxy)butyl prop-2-enoate

Details on test material:

- Name of test material (as cited in study report): Butandiol(1,4)diacrylat, Partie 3
- Physical state: liquid

Test animals

Species:

mouse

Strain:

other: "Tuebinger Maeuse"

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Weight at study initiation: 21-32g

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

other: Tragacanth

Details on exposure:

The doses were administered at concentrations of 0.5%, 1%, 2% and 20% preparations of the test substance in an aqueous emulsion with tragacanth.

Doses:

1600 mg/kg (20% emulsion), 200 mg/kg (2% emulsion), 100 mg/kg ( 1% emulsion), 50 mg/kg (0.5% emulsion) and 25 mg/kg (0.5% emulsion)

No. of animals per sex per dose:

5 animals per dose; in one dose group 3 male and 2 female / or 2 male and 3 female animals were used

Control animals:

no

Details on study design:

- Duration of observation period following administration: 7 days
- Frequency of observations and weighing: Group-wise documentation of clinical signs was performed over the 7 day study period.
Body weight was determined before the start of the study only, as it was needed for determination of dose.
- Necropsy of survivors performed: yes
- Other examinations performed: The clinical signs and findings were reported in summary form .

Statistics:

no data

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

ca. 50 mg/kg bw

Mortality:

after 7 days:
1600 mg/kg bw: 5/5
200 mg/kg bw: 5/5
100 mg/kg bw: 4/5
50 mg/kg bw: 2/5
25 mg/kg bw: 0/5

Clinical signs:

1600 mg/kg bw: immediatelly after injection: running around while staggering; accelarated breathing; later: lateral position; severe dyspnea; death within 2-4 hours;
200 mg/kg bw: Staggering (on application day), piloerection, death within 1,2 and 3 days. Animals which died last: severe apathy, scrubby fur, eyes stuck shut, no food uptake
100 mg/kg bw and lower concentrations: On the day of application nothing abnormal was detected; days following application: tremors (especially after touching the animals); light apathy; accelerated breathing; animals died after 2,3 und 6 days; surving animals: nothing abnormal could be detected 6 days after application

Gross pathology:

Organs of sacrificed animals: nothing abnormal detected;
animals that died: 2 animals had a light redness of the small intestine;